Lesaffre has acquired NattoPharma, a Norwegian nutraceutical company specializing in research and marketing of vitamin K2, in order to strengthen its presence in the global human nutrition and health market and confirms its commitment to accelerate its research and development activities.
This announcement completes the friendly public offer launched in February to acquire all outstanding shares of NattoPharma, a company listed on Euronext Expand Oslo.
As Lesaffre now holds more than 90% of the share capital of NattoPharma, a delisting and compulsory acquisition of the remaining shares will be carried out in due course.
As a global player in the field of fermentation and micro-organisms, Lesaffre has been expanding its capabilities in human nutrition and health for more than 15 years.
Through its business unit Gnosis by Lesaffre, Lesaffre is already an established supplier of Vitamin K2, an ingredient used in dietary supplements, with benefits in bone health and cardiovascular health.
The company expects NattoPharma to help Gnosis by Lesaffre expand the awareness about and access to the benefits of Vitamin K2 to support the health capital of consumers.
